DoD Taking Applications For $75K Horizon Grant

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Department of Defense is taking applications for its Horizon Award, which offers up to $75,000 in funding to support junior-level scientists to conduct impactful research with the mentorship of an experienced cancer researcher.

The award is for principal investigators, both pre-doctoral candidates and postdoctoral fellows are eligible, and mentors that have a strong record of funding and publications. The PI and mentor must be from the same organization.

They must address at least one of the congressionally directed FY15 PRCRP Topic Areas and are encouraged to address at least one of the FY15 PRCRP Military Relevance Focus Areas. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), or ovarian cancer will not be accepted.

The FY15 PRCRP Topic Areas are: cancers of the kidney, liver, pancreas, stomach or colorectal tract; melanoma and other skin cancers; myeloproliferative disorders; listeria vaccines for cancer; mesothelioma; and neuroblastoma. Liver and stomach cancer have been newly added for 2015.

The FY15 Military Relevance Focus Areas are: Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, and environmental carcinogens); and gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military members, veterans, and their beneficiaries.

Full applications are due Aug. 11. Clinical trials are not allowed and preliminary data are not required. The maximum period of performance is one year.

A pre-application is required through the electronic Biomedical Research Application Portal at http://eBRAP.org prior to the pre-application deadline.

Program announcements and general application instructions are available at www.grants.gov.

YOU MAY BE INTERESTED IN

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login